Has Neera Dahl, MD received payments from drug or device companies?

Yes. Drug and device makers reported $101,662 in general payments to Neera Dahl, MD across 93 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Neera Dahl, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Neera Dahl, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Neera Dahl, MD

Nephrology · Rochester, MNNPI 1336254002

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $74,402 of the $101,662 with a category attached, or 73.2%. 11 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 42.3% of the total. Reporting peaked in 2022 at $28,912 and has fallen 72.5% since, to $7,951 in 2025. Among nephrology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$101,662in general payments, 2019–2025

Across 93 payments — averaging $1093.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka America Pharmaceutical, Inc.$43K
Otsuka Pharmaceutical Development & Commercialization, Inc.$37K
Vertex$11K
GSK$6K
AstraZeneca$4K
Novartis$464
plus $589 from 5 others

$1,335,648in research payments, 2019–2025

Across 74 payments — averaging $18,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Vertex$621K
Kadmon Corporation LLC$308K
Otsuka Pharmaceutical Development & Commercialization, Inc.$118K
Sanofi$75K
Pfizer$65K
AstraZeneca$62K
plus $86K from 3 others

What the payments were for

Consulting fees$74,40273%
Speaking & faculty fees$19,98720%
Travel & lodging$4,9715%
Food & beverage$2,2422%
Education$610%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka America Pharmaceutical, Inc.	29	$43,043
Otsuka Pharmaceutical Development & Commercialization, Inc.	39	$37,052
Vertex	10	$11,327
GSK	4	$5,528
AstraZeneca	2	$3,660
Novartis	2	$464
Amgen	1	$140
Bard Peripheral Vascular, Inc.	2	$135
Astrazeneca UK Limited	1	$135
Fresenius USA Marketing, Inc.	1	$115
Janssen Scientific Affairs, LLC	2	$63

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

JYNARQUE$35,169
TOLVAPTAN$9,936
LOKELMA$1,945
SAMSCA$336
Tavneos$140
Velphoro$115

How this compares

$101,662 in reported general payments places this provider in the 95th percentile of 208 nephrology providers in Minnesota.

See all nephrology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$32,471

Medicare patients

208

Services billed

387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	16	$8,980
Potassium Citrate ErPotassium Citrate	41	$5,707
Torsemide	25	$495
Losartan Potassium	35	$373
Amlodipine Besylate	13	$245
Allopurinol	19	$54
Glipizide ErGlipizide	15	$46
Lisinopril	12	$25

Paid to pharmacies, not to this prescriber.

Other nephrology in Rochester

Fernando FervenzaRochester$102K
Nelson LeungRochester$32K
John LieskeRochester$31K
Leticia RolonRochester$30K
Nattawat KlomjitRochester$25K
Ladan ZandRochester$25K
Marie HoganRochester$19K
Kianoush Banaei KashaniRochester$19K
Aleksandra KuklaRochester$12K
Vicente TorresRochester$10K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →